<DOC>
	<DOCNO>NCT02475070</DOCNO>
	<brief_summary>The aim study ass vildagliptin dapagliflozin dissociate effect glucagon secretion mixed meal ingestion metformin-treated subject type 2 diabetes whether associated effect glucose homeostasis .</brief_summary>
	<brief_title>Vildagliptin Versus Dapagliflozin Glucagon</brief_title>
	<detailed_description>The aim study ass vildagliptin dapagliflozin dissociate effect glucagon secretion mixed meal ingestion metformin-treated subject type 2 diabetes whether associated effect glucose homeostasis . Subjects therefore treat vildagliptin dapagliflozin add-on metformin two week follow meal test glucagon level determine .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>1 . Written consent give . 2 . Patients type 2 diabetes treat stable dose metformin last three month 3 . Age 2070 year . 4 . HbA1c 6.58.5 % ( 4867 mmol/mol ) visit 1 . 5 . Ability complete study 1 . Use glucoselowering therapy metformin within three month prior visit 1 . 2 . A history secondary form diabetes , e.g. , Cushing 's syndrome acromegaly . 3 . Type 1 diabetes , positive GAD antibodies 4 . Estimated glomerular filtration rate &lt; 60 ml/min 5 . Acute infection may affect blood glucose control within 4 week prior visit 1 6 . Any history recent ( &lt; 2 week ) recurrent severe hypoglycemic episode . 7 . Any history acute pancreatitis 8 . Any history anaphylaxis , angioedema , exfoliative skin condition include StevensJohnson syndrome . 9 . Liver disease cirrhosis chronic active hepatitis 10 . History coronary heart disease heart failure class III IV 11 . Donation one unit ( 500 ml ) blood , significant blood loss equal least one unit blood within past 2 week blood transfusion within past 8 week . 12 . Treatment growth hormone chronic oral parenteral corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week prior visit 1 . 13 . Use investigational drug visit 1 within 30 day visit 1 , unsuitable study 14 . Hypersensitivity vildagliptin dapagliflozin compound tablet core</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>